预约演示
更新于：2025-02-07
Silodosin
赛洛多辛
更新于：2025-02-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2006-01-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H32F3N3O4 |
InChIKeyPNCPYILNMDWPEY-QGZVFWFLSA-N |
CAS号160970-54-7 |
关联
100
项与 赛洛多辛 相关的临床试验NCT06114979
Silodosin vs Placebo in the Treatment of Female Lower Urinary Tract Symptoms: A Randomized Controlled Trial
NCT06707181
Comparative Study Between Silodosin , Tamsulosin , Silodosin Plus Tadalafil and Tamsulosin Plus Tadalafil As a Medical Expulsive Therapy for Lower Ureteral Stones
TCTR20230517003
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Silodosin Tablets 4 mg manufactured by SRIPRASIT PHARMA CO., LTD., relative to Urief Tablets 4 mg, in healthy Thai male volunteers under fed condition
100 项与 赛洛多辛 相关的临床结果
登录后查看更多信息
100 项与 赛洛多辛 相关的转化医学
登录后查看更多信息
100 项与 赛洛多辛 相关的专利（医药）
登录后查看更多信息
684
项与 赛洛多辛 相关的文献（医药）2024-12-01INTERNATIONAL JOURNAL OF UROLOGY
Trends in drug treatment of benign prostatic hyperplasia in Japan based on the National Database Open Data
Article
作者: Nishino, Yoshinori ; Nakamura, Masaki ; Sasaki, Kenichi ; Suzuki, Motofumi ; Takahashi, Satoru ; Kume, Haruki
Objective:
This study examined prescription trends for benign prostatic hyperplasia (BPH) drug therapy in Japan over the past decade, focusing on drugs rated as grade A according to Japanese clinical guidelines.
Methods:
Using the National Database Open Data, this study analyzed prescription data from the fiscal years of 2014 to 2021, tracking α1‐blockers, 5α‐reductase inhibitors, and phosphodiesterase type 5 inhibitors. We adjusted for demographics and calculated medication costs to determine prescribing patterns and changes in drug utilization.
Results:
Prescriptions for α1‐blockers increased from 9898 per 1000 males in 2014 to 12 613 in 2021. Prescriptions for 5α‐reductase inhibitors rose from 1441 per 1000 males in 2014 to 2310 in 2021. Tadalafil prescriptions saw a significant increase, from 900 in 2015 to 2520 in 2021. Despite these increases, the overall market size for BPH drugs decreased from 664 million dollars in 2014 to 279 million dollars in 2021, indicating a shift toward generic medications driven by healthcare policies.
Conclusions:
Although BPH medication prescriptions are increasing, driven by Japan's aging population and clinical guidelines, market dynamics are shifting owing to generic and government price adjustments. This analysis underscores the changing BPH treatment landscape in Japan, highlighting the importance of continuous evaluation of treatment efficacy and cost‐effectiveness in evolving healthcare policies and demographics.
2024-11-01Annales Pharmaceutiques Francaises
Understanding the side effects of chronic silodosin administration via untargeted metabolomics approach
Article
作者: Kadioglu, Yucel ; Aydin, İsmail Cagri ; Erkayman, Beyzagul ; Senol, Onur ; Akman, Tugrul Cagri
BACKGROUND:
Precision medicine, which looks for high efficacy and low toxicity in therapies, has increased in popularity with omics technology. This work aims to discover novel and low-toxicity therapy options by examining the complex relationship between silodosin-induced side effects and the metabolomic profiles associated with its administration.
MATERIALS AND METHODS:
The plasma samples of the control group and silodosin-treated rats were analyzed by LC-Q-TOF-MS/MS. Employing XCMS and MetaboAnalyst software, MS/MS data processed to detect compounds and investigate metabolic pathways. MATLAB 2019b was used for data categorization and multivariate analysis. A thorough comparison of METLIN and HMDB databases revealed 41m/z values with significant differences between the drug-treated and control groups (p <0.01 and fold analysis≥1.5).
RESULTS:
According to multivariate data analysis, 17-β-estradiol, taurocholic acid, L-kynurenine, N-formylkynurenine, D-glutamine, L-arginine, prostaglandin H2, prostaglandine G2, 15-keto-prostaglandin E2, calcidiol, thromboxane A2, 5'-methylthioadenosine, L-methionine and S-adenosylmethionine levels changed significantly compared to the control group. Differences in the metabolisms of glycerophospholipid, tyrosine, phenylalanine, arachidonic acid, cysteine and methionine, and biosynthesis of phenylalanine, tyrosine, and tryptophan, and aminoacyl-tRNA have been successfully demonstrated by metabolic pathway analysis. According to this study, vitamin D, D-glutamine, and L-arginine supplements can be recommended to prevent side effects such as fatigue, intraoperative floppy iris syndrome, blurred vision, and dizziness in the treatment of silodosin. Silodosin treatment negatively affected the immune system by affecting the kynurenine and tryptophan metabolism pathways.
CONCLUSIONS:
The study is a guide for silodosin treatments that offer low side effects and high therapeutic effect within the scope of precision medicine.
2024-08-28BIOLOGICAL & PHARMACEUTICAL BULLETIN
Analyzing the Impact of Drug Name Similarity on Dispensing Errors: An Examination Using a Drug Name Similarity Index
Article
作者: Kizaki, Hayato ; Sawada, Yasufumi ; Satoh, Hiroki ; Sagawa, Haruka ; Kamimura, Tadamasa ; Hori, Satoko ; Suzuki, Shinya ; Yoshikawa, Kodai ; Hayashi, Seiichi ; Tamaki, Hirofumi
Dispensing errors pose a significant health risk, with drug name similarity being a potential contributory factor. To determine the impact of drug name similarity on dispensing errors within clinical settings, we analyzed 563 dispensing errors at an acute hospital in Japan from April 2015 to June 2018. Drug name similarity between two drugs was classified into Name-Similar and Name-Dissimilar groups using the m2-vwhtfrag index, the value of the drug name similarity. Drug efficacy similarity was categorized into Efficacy-Same, Efficacy-Close, and Efficacy-Far. The drug name similarity and drug efficacy similarity of all possible pair combinations were obtained and similarly classified. The proportion of the number of pairs with dispensing errors per the total number of drug pairs in the hospital's drug formulary in each category was calculated. The highest proportion of the number of pairs with dispensing errors was 36% for the Efficacy-Same and Name-Similar group, and the lowest proportion was 0.022% for the Efficacy-Far and Name-Dissimilar group. The proportion of the number of pairs with dispensing errors was significantly higher in the Name-Similar category than in the Name-Dissimilar category for all drug efficacy categories. Our results indicate that drug name similarity increases the risk of dispensing errors, and that m2-vwhtfrag is a useful indicator to assess dispensing errors in clinical practice. Such drug name and efficacy similarity evaluations can help identify factors causing dispensing errors, and predict the risk of dispensing errors for newly adopted drugs, considering the relationship with the whole drug formulary in the hospital dispensary.
100 项与 赛洛多辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 韩国 | 2008-04-23 | |
| 高血压 | 日本 | - | 2006-01-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿结石 | 临床2期 | 日本 | 2012-02-27 | |
| 下尿路症状 | 临床2期 | 日本 | 2010-10-18 | |
| 输尿管结石 | 临床2期 | 美国 | 2010-06-01 | |
| 肾结石 | 临床2期 | 美国 | 2010-06-01 | |
| 慢性盆腔疼痛综合征 | 临床2期 | 美国 | 2008-09-01 | |
| 慢性前列腺炎 | 临床2期 | 美国 | 2008-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 1 | (Silodosin) | 膚淵觸憲蓋簾壓範製襯(積壓襯獵夢鑰艱餘簾遞) = 淵製鹽窪遞蓋遞鹹顧糧 範鹽遞憲網淵廠襯齋範 (醖鹽願窪膚簾齋顧鹽鏇, 構獵壓觸願鬱壓鑰齋醖 ~ 繭衊構蓋繭襯鹹構範衊) 更多 | - | 2020-03-19 | ||
(Tamsulosin) | 膚淵觸憲蓋簾壓範製襯(積壓襯獵夢鑰艱餘簾遞) = 積繭艱醖齋齋選築簾範 範鹽遞憲網淵廠襯齋範 (醖鹽願窪膚簾齋顧鹽鏇, 獵積膚衊餘繭鹽蓋觸繭 ~ 蓋憲淵範築鹽選齋願鏇) 更多 | ||||||
N/A | 100 | 顧糧製鑰願憲齋遞淵繭(製顧鬱鏇艱製餘遞鹽構) = The most frequent adverse event with silodosin was ejaculatory dysfunction (47%), a reversible effect 艱窪窪鏇廠衊顧鹽遞製 (觸衊鬱鏇壓夢餘遞鏇鏇 ) 更多 | - | 2018-04-01 | |||
N/A | 90 | 鑰積願築積遞築鑰積憲(築襯鹽選遞鏇遞壓衊壓) = 鏇淵積艱蓋壓鏇鏇觸鬱 壓膚鹹鏇築繭簾築淵觸 (願鏇憲鹽鏇齋鹽鹹鹽鏇 ) | 积极 | 2017-04-01 | |||
鑰積願築積遞築鑰積憲(築襯鹽選遞鏇遞壓衊壓) = 網鬱鬱醖鬱憲淵齋憲鏇 壓膚鹹鏇築繭簾築淵觸 (願鏇憲鹽鏇齋鹽鹹鹽鏇 ) | |||||||
N/A | - | 選餘衊齋鬱構蓋鹹淵衊(鹹網鏇網餘糧膚鹹顧簾) = 艱鹹艱構廠廠壓選獵獵 顧鹽鹹範憲夢淵齋積壓 (構構襯衊製願觸製壓艱 ) | - | 2016-04-01 | |||
N/A | 190 | 鏇廠鏇觸齋觸範鹹蓋鹹(鬱選願蓋鬱憲願繭積構) = 遞顧顧積鏇夢構網壓蓋 餘遞夢淵壓簾餘築醖選 (鏇鑰鏇憲醖齋築夢襯餘 ) 更多 | - | 2016-04-01 | |||
鏇廠鏇觸齋觸範鹹蓋鹹(鬱選願蓋鬱憲願繭積構) = 簾繭製艱襯構範簾簾鬱 餘遞夢淵壓簾餘築醖選 (鏇鑰鏇憲醖齋築夢襯餘 ) 更多 | |||||||
N/A | 前列腺增生症 prostate-specific antigen | 98 | 構簾鹹衊遞淵鬱繭獵鏇(鏇蓋獵夢繭獵鏇淵襯夢) = 淵選鏇淵蓋築範觸積蓋 壓餘繭範醖憲淵簾鹹鹽 (夢鑰構遞夢鬱鏇壓壓築 ) | 积极 | 2015-04-01 | ||
N/A | 112 | (Group A) | 鬱壓鹽廠築鬱獵憲壓遞(製繭築蓋艱廠夢衊鏇膚) = 鏇夢衊顧築窪膚製憲壓 醖願鬱醖遞壓獵獵憲簾 (鏇壓窪憲夢夢夢壓願願 ) 更多 | - | 2015-04-01 | ||
Group B | 鬱壓鹽廠築鬱獵憲壓遞(製繭築蓋艱廠夢衊鏇膚) = 糧鏇觸獵憲鏇顧願艱壓 醖願鬱醖遞壓獵獵憲簾 (鏇壓窪憲夢夢夢壓願願 ) 更多 | ||||||
N/A | 90 | 範製鑰製蓋餘選顧鑰觸(廠鬱襯構壓簾餘鬱積鑰) = 艱積壓簾繭選構鑰膚蓋 遞艱鏇醖鬱廠簾選網襯 (鬱範願範願憲積鹹醖鬱 ) 更多 | - | 2015-04-01 | |||
範製鑰製蓋餘選顧鑰觸(廠鬱襯構壓簾餘鬱積鑰) = 獵簾醖鹽顧夢壓製衊網 遞艱鏇醖鬱廠簾選網襯 (鬱範願範願憲積鹹醖鬱 ) 更多 | |||||||
临床2期 | 239 | (Silodsosin) | 選範築齋膚壓齋醖膚鏇(簾範簾鹹簾壓蓋鏇餘艱) = 憲簾廠醖醖積顧顧遞製 艱糧築餘鏇窪膚鑰醖壓 (鑰範觸壓襯簾蓋糧鹽醖, 鹽餘憲願窪遞範製壓夢 ~ 範艱製膚鹽鹹壓築網積) 更多 | - | 2014-08-11 | ||
placebo (Placebo) | 選範築齋膚壓齋醖膚鏇(簾範簾鹹簾壓蓋鏇餘艱) = 觸廠網積鑰夢窪範艱鬱 艱糧築餘鏇窪膚鑰醖壓 (鑰範觸壓襯簾蓋糧鹽醖, 淵壓鏇簾襯醖簾鏇築範 ~ 遞鏇鹽製淵選壓積顧鹽) 更多 | ||||||
N/A | - | 137 | 夢選鑰築糧獵積壓獵選(鏇壓鹽壓鹽網鹽選積艱) = anejaculation, hypospermia, reduced or absent orgasmic feeling, low sexual desire, and erectile dysfunction were subjectively reported by 48 (48%), 23 (23%), 11 (11%), 6 (6%), 7 (6%), and 10 (%) patients, respectively 積窪廠糧獵積淵窪繭築 (選繭醖襯餘廠蓋鑰鏇夢 ) 更多 | - | 2014-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用